You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Baxter
AstraZeneca
Harvard Business School
Moodys

Last Updated: July 3, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020405


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 020405 describes LANOXIN, which is a drug marketed by Covis Pharma Bv and Concordia and is included in two NDAs. It is available from four suppliers. Additional details are available on the LANOXIN profile page.

The generic ingredient in LANOXIN is digoxin. There are ten drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the digoxin profile page.
Summary for 020405
Tradename:LANOXIN
Applicant:Concordia
Ingredient:digoxin
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020405
Medical Subject Heading (MeSH) Categories for 020405
Suppliers and Packaging for NDA: 020405
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LANOXIN digoxin TABLET;ORAL 020405 NDA AUTHORIZED GENERIC Par Pharmaceutical Inc. 49884-494 49884-494-01 100 TABLET in 1 BOTTLE (49884-494-01)
LANOXIN digoxin TABLET;ORAL 020405 NDA AUTHORIZED GENERIC Par Pharmaceutical Inc. 49884-494 49884-494-10 1000 TABLET in 1 BOTTLE (49884-494-10)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.0625MG
Approval Date:Sep 30, 1997TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.125MG
Approval Date:Sep 30, 1997TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength0.1875MG
Approval Date:Sep 30, 1997TE:RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Mallinckrodt
Merck
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.